HDAC9 and neoplasm: In vivo studies using target tumour cell lines were not conducted for histone deacetylase (HDAC) inhibitors, such as romidepsin (indication: PTCL) and vorinostat (indication: CTCL), which showed tumour growth inhibitory activity using other tumour cell lines.